Efficacy and Safety Completed Phase 2 Trials for Rivoceranib (DB14765)

IndicationStatusPhase
DBCOND0085675 (Efficacy and Safety)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03660761Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant TumorsTreatment